Clearwater Paper offers asymmetric recovery upside from pricing normalization and deleveraging, but its CCC+ balance sheet and refinancing deadlines make execution a prerequisite for the bullish thesis.
Overview
Clearwater Paper is now a focused North American SBS paperboard producer after selling its consumer tissue division to Sofidel for **$1.06 billion** and acquiring Graphic Packaging’s Augusta mill for approximately $700 million in 2024. The transactions created a 1.42 million-short-ton asset base, roughly 11% of North American SBS capacity, serving foodservice, food and beverage, cosmetics, pharmaceutical, and commercial-graphics converters. Its independent supplier model avoids competing with customers downstream, while Manchester Industries provides localized fulfillment and switching costs. Financially, the company is still at the cyclical trough: Q2 2026 sales fell 4.3% to $374.8 million as realized prices dropped 9% to $1,077 per ton, despite 8% shipment growth to 328,722 tons; Adjusted EBITDA was negative $8.2 million versus positive $39.9 million. Management nevertheless guides to Q3 Adjusted EBITDA of $20 million-$30 million, maintained 2026 sales guidance of $1.4 billion-$1.5 billion, and expects positive full-year FCF. **The key near-term catalysts are price increases, Cypress Bend savings, lower outage spending, debt reduction, and refinancing.** The valuation is highly asymmetric: the five-year base case reaches $70.60 per share, but the CCC+ rating, maturity wall, customer concentration, and industry pricing risk justify a high-risk recovery characterization.